Remdesivir Patent Expiration

1. Veklury patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8318682 GILEAD SCIENCES INC 1′substituted carba-nucleoside analogs for antiviral treatment
Apr, 2029

(4 years from now)

USRE46762 GILEAD SCIENCES INC 1′-substituted carba-nucleoside analogs for antiviral treatment
Apr, 2029

(4 years from now)

US8008264 GILEAD SCIENCES INC 1′-substituted carba-nucleoside analogs for antiviral treatment
Sep, 2029

(5 years from now)

US10065958 GILEAD SCIENCES INC Methods and compounds for treating Paramyxoviridae virus infections
Sep, 2031

(7 years from now)

US11492353 GILEAD SCIENCES INC Methods and compounds for treating Paramyxoviridae virus infections
Dec, 2031

(7 years from now)

US9724360 GILEAD SCIENCES INC Methods for treating Filoviridae virus infections
Oct, 2035

(11 years from now)

US9949994 GILEAD SCIENCES INC Methods for treating Filoviridae virus infections
Oct, 2035

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8318682

(Pediatric)

GILEAD SCIENCES INC 1′substituted carba-nucleoside analogs for antiviral treatment
Oct, 2029

(5 years from now)

USRE46762

(Pediatric)

GILEAD SCIENCES INC 1′-substituted carba-nucleoside analogs for antiviral treatment
Oct, 2029

(5 years from now)

US8008264

(Pediatric)

GILEAD SCIENCES INC 1′-substituted carba-nucleoside analogs for antiviral treatment
Mar, 2030

(5 years from now)

US10065958

(Pediatric)

GILEAD SCIENCES INC Methods and compounds for treating Paramyxoviridae virus infections
Mar, 2032

(7 years from now)

US11492353

(Pediatric)

GILEAD SCIENCES INC Methods and compounds for treating Paramyxoviridae virus infections
Jun, 2032

(7 years from now)

US9949994

(Pediatric)

GILEAD SCIENCES INC Methods for treating Filoviridae virus infections
Apr, 2036

(11 years from now)

US9724360

(Pediatric)

GILEAD SCIENCES INC Methods for treating Filoviridae virus infections
Apr, 2036

(11 years from now)

US11382926 GILEAD SCIENCES INC Methods for treating Arenaviridae and Coronaviridae virus infections
Sep, 2036

(12 years from now)

US11007208 GILEAD SCIENCES INC Methods for treating arenaviridae and coronaviridae virus infections
Sep, 2036

(12 years from now)

US10695361 GILEAD SCIENCES INC Methods for treating arenaviridae and coronaviridae virus infections
Sep, 2036

(12 years from now)

US11382926

(Pediatric)

GILEAD SCIENCES INC Methods for treating Arenaviridae and Coronaviridae virus infections
Mar, 2037

(12 years from now)

US10695361

(Pediatric)

GILEAD SCIENCES INC Methods for treating arenaviridae and coronaviridae virus infections
Mar, 2037

(12 years from now)

US11007208

(Pediatric)

GILEAD SCIENCES INC Methods for treating arenaviridae and coronaviridae virus infections
Mar, 2037

(12 years from now)

US11266681 GILEAD SCIENCES INC Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
Jul, 2038

(13 years from now)

US10675296 GILEAD SCIENCES INC Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
Jul, 2038

(13 years from now)

US11266681

(Pediatric)

GILEAD SCIENCES INC Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
Jan, 2039

(14 years from now)

US10675296

(Pediatric)

GILEAD SCIENCES INC Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
Jan, 2039

(14 years from now)

US11491169 GILEAD SCIENCES INC Remdesivir treatment methods
May, 2041

(16 years from now)

US11903953 GILEAD SCIENCES INC Remdesivir treatment methods
May, 2041

(16 years from now)

US11903953

(Pediatric)

GILEAD SCIENCES INC Remdesivir treatment methods
Nov, 2041

(17 years from now)

US11491169

(Pediatric)

GILEAD SCIENCES INC Remdesivir treatment methods
Nov, 2041

(17 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-183) Jan 21, 2025
New Patient Population(NPP) Apr 25, 2025
New Chemical Entity Exclusivity(NCE) Oct 22, 2025
M(M-301) Jul 13, 2026
Pediatric Exclusivity(PED) Jan 13, 2027

NCE-1 date: 13 January, 2026

Market Authorisation Date: 22 October, 2020

Treatment: Treatment of coronavirus disease 2019 (covid-19) in adults and pediatric patients (weighing at least 40 kg) requiring hospitalization; Treatment of coronavirus disease 2019 (covid-19) in non-hospitali...

Dosage: SOLUTION; POWDER

More Information on Dosage

VEKLURY family patents

Family Patents